Vaxart Stock Is Surging As Its Oral COVID-19 Vaccine Can Potentially Trigger Immunity Against Variants
May 04, 2021 at 08:59 AM EDT
Vaxart Inc has announced new data from the Phase 1 trial evaluating its oral COVID-19 vaccine candidate, dubbed as VXA-CoV2-1.
